Abstract

Patients with hepatocellular carcinoma (HCC) have poor long-term survival following curative resection because of the high rate of tumor early recurrence. Little is known about the trajectory of genomic evolution from primary to early-recurrent HCC. In this study, we performed whole-genome sequencing (WGS) on 40 pairs of primary and early-recurrent hepatitis B virus (HBV)-related HCC tumors from patients who received curative resection, and from four patients whose primary and recurrent tumor were extensively sampled. We identified two recurrence patterns: de novo recurrence (18/40), which developed genetically independently of the primary tumor and carried different HCC drivers, and ancestral recurrence (22/40), which was clonally related to the primary tumor and progressed more rapidly than de novo recurrence. We found that the recurrence location was predictive of the recurrence pattern: distant recurrence tended to display the de novo pattern, whereas local recurrence tended to display the ancestral pattern. We then uncovered the evolutionary trajectories based on the subclonal architecture, driver-gene mutations, and mutational processes observed in the primary and recurrent tumors. Multi-region WGS demonstrated spatiotemporal heterogeneity and polyclonal, monophyletic dissemination in HCC ancestral recurrence. In addition, we identified recurrence-specific mutations and copy-number gains in BCL9, leading to WNT/β-catenin signaling activation and an immune-excluded tumor microenvironment, which suggests that BCL9 might serve as a new therapeutic target for recurrent HCC. Collectively, our results allow us to view with unprecedented clarity the genomic evolution during HBV-related HCC early recurrence, providing an important molecular foundation for enhanced understanding of HCC with implications for personalized therapy to improve patient survival.

Details

Title
Whole-genome sequencing reveals the evolutionary trajectory of HBV-related hepatocellular carcinoma early recurrence
Author
Shao-Lai, Zhou 1   VIAFID ORCID Logo  ; Zheng-Jun, Zhou 2 ; Cheng-Li, Song 3 ; Hao-Yang, Xin 1 ; Hu Zhi-Qiang 1 ; Chu-Bin, Luo 1 ; Yi-Jie, Luo 4 ; Li, Jia 1 ; Dai Zhi 2   VIAFID ORCID Logo  ; Xin-Rong, Yang 1   VIAFID ORCID Logo  ; Ying-Hong, Shi 1 ; Wang, Zheng 1 ; Xiao-Wu, Huang 1 ; Fan, Jia 5   VIAFID ORCID Logo  ; Zhou, Jian 5   VIAFID ORCID Logo 

 Fudan University, Department of Liver Surgery and Transplantation, Zhongshan Hospital, Shanghai, China (GRID:grid.8547.e) (ISNI:0000 0001 0125 2443); Fudan University, Liver Cancer Institute, Zhongshan Hospital, Shanghai, China (GRID:grid.8547.e) (ISNI:0000 0001 0125 2443) 
 Fudan University, Liver Cancer Institute, Zhongshan Hospital, Shanghai, China (GRID:grid.8547.e) (ISNI:0000 0001 0125 2443) 
 Novogene Bioinformatics Institute, Beijing, China (GRID:grid.410753.4); Dalian Medical University, Institute of Cancer Stem Cell, Dalian, China (GRID:grid.411971.b) (ISNI:0000 0000 9558 1426) 
 Novogene Bioinformatics Institute, Beijing, China (GRID:grid.410753.4) 
 Fudan University, Department of Liver Surgery and Transplantation, Zhongshan Hospital, Shanghai, China (GRID:grid.8547.e) (ISNI:0000 0001 0125 2443); Fudan University, Liver Cancer Institute, Zhongshan Hospital, Shanghai, China (GRID:grid.8547.e) (ISNI:0000 0001 0125 2443); Fudan University, State Key Laboratory of Genetic Engineering, Shanghai, China (GRID:grid.8547.e) (ISNI:0000 0001 0125 2443) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
ISSN
20959907
e-ISSN
20593635
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2622678385
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.